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OBJECTIVES: To assess and compare patients’ access to biologic anti-RA drugs in 
selected CEE countries (Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Poland, 
Romania, Russia, Serbia, Slovakia, Slovenia) and to analyse the determinants of dif-
ferences between countries. METHODS: This is a multi-country survey study, based 
on a combination of desk research and direct contact with national RA stakeholders. 
Data was collected using a pre-deﬁned questionnaire. Affordability was measured 
using affordability index, calculated comparing the health care expenditures index to 
the price index, using Poland as an index of 1. A higher index indicates more limited 
affordability. RESULTS: The percentage of patients on biologic treatment in 2009 
was highest in Hungary (5%), followed by Slovenia (4.5%), Slovakia (3.5%), Czech 
(2.92%), Romania (2.19%), Estonia (1.8%), Croatia (1.4%) and Serbia (1.3%), 
lowest in Poland (1%). Inﬂiximab, etanercept, adalimumab and rituximab are 
included in the reimbursement system in all countries (latest in Bulgaria), abatacept 
and tocilizumab—only in Slovakia. In Slovenia public payer covered 75% of the price, 
25% was covered by supplementary health insurance; in Bulgaria public payer covered 
50% of etanercept and adalimumab costs, and 75% of rituximab cost. In other 
countries biological drugs were reimbursed in 100%. Affordability index for biologic 
drugs was lowest in Slovenia (0.4), followed by Hungary (0.6), Czech Rep. (0.7), 
Estonia (0.9), while countries with health care expenditures below 500 USD/capita 
(Bulgaria, Romania and Serbia) had the highest indexes (1.4–1.9). In each country 
national guidelines deﬁned which patients were eligible for biologic tretament, and 
some also deﬁned the sequence in which drugs should be used. DAS28 of over 5.1. 
and failure of 2 or more disease-modifying anti-RA drugs, including methotrexate, 
are commonly used criteria. CONCLUSIONS: The most important factors of limited 
access to biologic anti-RA treatment CEE region are macroeconomic conditions and 
restrictive treatment guidelines.
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OBJECTIVES: Payers may employ utilization management tools that restrict access 
to FDA-approved therapies in favor of off-label therapies for treating disorders such 
as ﬁbromyalgia (FM). It is appropriate to review the body of evidence that exists to 
support these decisions. We assessed the quality and quantity of published randomized 
clinical trials (RCTs), as well as reviewed the trial evidence presented in compendia 
and guidelines, for commonly prescribed FM treatments. METHODS: A literature 
review was conducted using MEDLINE, Cochrane Library, and EMBASE for FM 
RCTs published January 2000 to June 2009. Two raters reviewed the quality of each 
RCT using the Jadad Quality Score. RCTs published prior to 2000 and cited in sys-
tematic reviews with published Jadad scores supplemented the review. Trial evidence 
cited in Drugdex and AHFS-DI compendia and the 2005 American Pain Society (APS) 
guideline were also reviewed. RESULTS: The 2000–2009 literature review yielded 19 
RCTs; the supplemental review yielded an additional 14 RCTs. When comparing 
across FM treatments, the FDA-approved therapies reported high-quality scores and 
had many more study subjects reported in published RCTs compared to off-label 
therapies. A review of compendia showed pregabalin was the only FM therapy cited 
in both Drugdex and AHFS-DI. However, the APS guideline, last updated in 2005, 
recommended off-label therapies and cited gabapentin and the FDA-approved prega-
balin as “experimental” treatments for FM. The off-label therapies nortriptyline and 
cyclobenzaprine were not listed as treatments for FM in either compendia, and many 
off-label and FDA-approved therapies were not speciﬁcally cited in the guideline. 
CONCLUSIONS: Formulary decision-makers should carefully consider the currency 
and quality of the body of evidence cited in compendia and guidelines, and should 
compare listings to recent high-quality published RCTs when considering utilization 
management tools for the treatment of FM.
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OBJECTIVES: Little is known about the burden of rheumatoid-arthritis (RA). The 
study objectives were to present an overview of the burden of RA in Ontario using 
survey and administrative data. METHODS: Records of all Ontarians who partici-
pated in the Canadian Community Health Survey (CCHS), cycle 1.1 (2000/2001) and 
provided consent to data linkage were linked to the Ontario Health Insurance Program 
(OHIP) physician claims database and the Discharge Abstract Database (DAD) In-
Patient (i.e. hospitalization) and Day-Procedure databases. Two criteria were used to 
identify RA patients (N = 233): 1) self-reported physician-diagnosed RA in CCHS; 
and 2) ICD-9 diagnosis code of RA in OHIP. A control group matched by age and 
gender was created (N = 688). Socio-demographic variables, medical characteristics, 
health-related quality of life and one-year physician, day procedures and hospitaliza-
tion costs were determined. CCHS sample weights were applied to represent the 
Ontario population. Logistic regressions, Tobit and Generalized Linear Model models 
were used to identify predictors of medical characteristics, utility and cost data, 
respectively. Bootstrap techniques were applied for the cost analyses. RESULTS: The 
mean age of the population was 59 years old and 75% were female. Compared to the 
control group, RA Individuals were statistically more likely to: be obese, reside in an 
urban community, be female, have more comorbidities and a lower HRQoL. No 
statistical differences were observed in terms of costs even after covariate adjustment. 
CONCLUSIONS: Although drug costs were not included, these results indicate that 
the burden of RA is considerable.
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OBJECTIVES: The aim was to estimate the prevalence of rheumatoid arthritis (RA) 
between 2003 and 2007, examine the real-life treatment patterns, and estimate the 
cost of managing RA in Taiwan. METHODS: A retrospective analysis of the medical 
claims data from the National Health Insurance Research Database (NHIRD) from 
years 2003–2007 was conducted. Eligible patients were deﬁned as having 1) an out-
patient visit with ICD9 code = 714.0; 2) an inpatient admission with the ICD9 code 
= 714.0; or 3) a catastrophic card for RA. Medication records were extracted. Informa-
tion on treatment with NSAIDs, DMARDs, and bio-DMARDs was extracted from 
the recorded diagnosis. RESULTS: The prevalence rate of RA in Taiwan was found 
to be around 0.4%. Majority of the patients identiﬁed were on NSAIDs (∼81%), while 
the proportion of patients treated with DMARDs increased from 26% to >35% during 
the study period. In the ﬁrst year from initial diagnosis, 13% to 17% patients were 
treated with DMARDs and 75% with NSAIDs. Etanercept was the ﬁrst bio-DMARD 
approved for use in RA in Taiwan in 2003; since its introduction, both the number 
and proportion of RA patients treated with etanercept increased sharply to 2284 by 
the end of 2007. Out of 2284, TB was reported in 55 patients, 45 of which were new 
cases. The average duration from starting etanercept to the date of a TB diagnosis 
was 461 days. The mean cost per person increased from 379 in 2003 to US$703 in 
2007, i.e. nearly doubled. CONCLUSIONS: The ﬁndings provide an estimate of RA 
prevalence and show the signiﬁcant medical cost of managing RA to the national 
health care system in Taiwan. A key limitation of the study is that the claims data do 
not have biological information on disease status and the medical reasons for treat-
ment failure or discontinuation.
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OBJECTIVES: Little is known about the health status and costs of individuals with 
osteo-arthritis (OA) in Ontario. The study objectives were to estimate the burden of 
OA in Ontario using health survey and administrative data. METHODS: The records 
of all Ontarians who participated in the Canadian Community Health Survey (CCHS), 
cycle 1.1 (2000/2001) and provided consent to data linkage were linked to the Ontario 
Health Insurance Program (OHIP) physician claims database and the Discharge 
Abstract Database (DAD) In-Patient (i.e. hospitalization) and Day-Procedure data-
bases. OA individuals (N = 4,331) were identiﬁed using CCHS 1.1. A control group 
matched by age and gender was created (N = 1,477). Socio-demographic variables, 
medical characteristics, health-related quality of life (HRQoL) and one-year physician, 
day procedures and hospitalization costs were determined. CCHS sample weights were 
applied to the data to represent the Ontario population. Logistic regressions, Tobit 
and Generalized Linear Model models were used to identify predictors of medical 
characteristics, utility and cost data, respectively. Bootstrap techniques were applied 
for the cost analyses. RESULTS: The mean age of the population was 66 years old 
and 74% were female. Compared to the control group, OA individuals were statisti-
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cally more likely to: be female, be less physically active, be overweight or obese, reside 
in an urban community, have more comorbidities, have a lower HRQoL and a lower 
household income. The 1-year physician, day procedure and hospitalization costs were 
statistically higher in the OA group. CONCLUSIONS: These results indicate that the 
humanistic and economic burden of OA in Ontario is considerable.
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OBJECTIVES: This study examined two approaches to estimate drug dosing of inf-
liximab, a commonly used biologic with weight-based dosing, for patients with rheu-
matoid arthritis (RA). METHODS: A national commercial database was utilized to 
analyze patients having a medical claim of inﬂiximab therapy initiated between 
January 2004 and December 2007. Inclusion criteria were patient age ≥18, ≥2 RA 
diagnosis codes during treatment with inﬂiximab, and 365 days of persistence with 
inﬂiximab. Patients were excluded if they had other selected inﬂammatory diseases, 
had medical/ pharmacy claims of anti-TNFs during 6 months prior to the inﬂiximab 
index date, or a record of taking abatacept or rituximab while on inﬂiximab. Two 
methods were compared for estimating dosing of inﬂiximab. Method I, which has 
been previously published, estimated dosing by dividing the plan’s allowed cost of 
inﬂiximab by the wholesale acquisition cost (WAC), adjusting for WAC at time of 
each claim. Method II, a novel approach, used a propensity matching approach to 
impute patient’s weight onto the commercial database. Since inﬂiximab has weight-
based dosing, combining the cost of drug with patient weight allowed for an estimate 
of dosing. Dosing was expressed as the number of 100 mg vials of inﬂiximab. Calcu-
lated drug dosing using the two methods were compared in terms of means, medians, 
and correlation coefﬁcients. RESULTS: There were 20,172 drug dosing events in our 
sample. Median dose was slightly higher under Method I (3.76 vials) than under 
Method II (3.39 vials). Mean overall dosing levels were very consistent: 4.01 vials 
under Method I and 4.11 vials under Method II. Correlations among the two measures 
were high (rho = 0.75). CONCLUSIONS: Consistent calculations of inﬂiximab drug 
dosing were obtained using two estimation approaches. Since several commercial 
databases lack direct information on weight-based drug dosing, such estimation 
methods may be useful.
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OBJECTIVES: To evaluate differences in demographics and comorbid conditions in 
patients with rheumatoid arthritis (RA) taking adalimumab, etanercept, or inﬂiximab 
and to compare their health care utilization/costs six months prior to the start of their 
ﬁrst year of persistent tumor necrosis factor inhibitor (anti-TNF) therapy. METHODS: 
A national commercial benchmark database was utilized to identify patients having a 
medical or pharmacy claim of an index biologic therapy started between January 2004 
and December 2007. Inclusion criteria were patient age ≥18, ≥2 RA diagnosis codes 
(ICD-9 code 714.xx), and 365 days of treatment with the index anti-TNF agent. 
Patients were excluded if they had a diagnosis of select inﬂammatory conditions, had 
medical/pharmacy claims of anti-TNFs during 6 months prior to anti-TNF index date, 
or evidence of taking abatacept or rituximab while on anti-TNF. Continuous variables 
were summarized with means and standard deviations. Differences in means were 
tested with analysis of variance (ANOVA). Discrete variables were summarized by 
counts and percentages with chi square used to test for differences. RESULTS: A total 
of 4886 patients met inclusion criteria: adalimumab = 1279 (26%), etanercept = 2277 
(47%), and inﬂiximab = 1330 (27%). In all cohorts, the majority of patients were 
female (75%). There was a signiﬁcant difference in mean age (years, ± SD) across the 
three cohorts: adalimumab (55, ± 12), etanercept (54, ± 12), and inﬂiximab (62, ± 13) 
(p = .0001). Inﬂiximab patients had signiﬁcantly higher rates of diabetes, anemia, 
GERD, osteoarthritis, osteoporosis, and cardiovascular diseases than adalimumab or 
etanercept. Six months prior to the start of therapy, inﬂiximab patients had signiﬁ-
cantly higher rates of health care utilization (radiology and ofﬁce visits) compared to 
adalimumab or etanercept. CONCLUSIONS: When examining baseline characteristics 
of RA patients taking adalimumab, etanercept, or inﬂiximab, results showed that 
inﬂiximab patients were older, had higher comorbidity burden, and higher utilization 
of select health care services. Baseline characteristics should be adjusted for in-com-
parative analyses of anti-TNF drug utilization.
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OBJECTIVES: Patient education is a vital component of effective disease management 
and health promotion. People worldwide rely on the internet to resolve issues or obtain 
information related to any health condition. The information available on the web 
though easily accessible, lacks regulatory control and is subject to manipulation. This 
calls for a need to authenticate the information available on the web. In this study, 
we evaluated the quality and content of websites providing information on osteopo-
rosis patient education by employing the widely accepted criteria. METHODS: About 
210 websites providing patient education were retrieved from the meta search engine, 
45 of which provided patient information on osteoporosis and were thus considered 
for evaluation. These health related websites were evaluated by 10 health care profes-
sionals for their HON Code compliance, their adherence to core education concepts 
and the HSWG criteria. RESULTS: Most of the sites were found to be compliant with 
the basic criteria stated by the HSWG. Only 11 of the 45 sites evaluated were HON 
Code compliant. A certain degree of variability in the quality of information of osteo-
porosis patient education with respect to core educational concepts was observed. 
CONCLUSIONS: Inclusion of helpful audio-visual descriptions, effective in-site 
search options, live conversations with experts and easier feedback mechanisms can 
be of signiﬁcant help and can further help to fulﬁll the HSWG criteria and thereby 
enhancing the quality of patient information related to osteoporosis on the web.
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OBJECTIVES: Recent trend in the number of primary total hip arthroplasty (THA) 
and total knee arthroplasty (TKA) in the US has suggested a massive future demand 
for THA and TKA. It is unknown if this trend is the same in Germany as they have 
slower growth rate in obesity compared to US. The purpose of our study was to 
describe the recent trend of primary THA and TKA in Germany. METHODS: Registry 
data on THA and TKA, collected between 2004 and 2008, were obtained from the 
German Bundesgeschäftsstelle für Qualitätssicherung (BQS). RESULTS: During the 
year 2008, approximately 156,887 primary THA and 146,052 TKA were performed. 
This was a 14% increase in THA and a 32% increase in TKA compared to the year 
2004. The number of annual increase in surgery was 6,848 (R-square, 88%) for THA 
and 8,875 (R-squares, 99%) for TKA. During this time period, the proportion of 
non-cemented THA has increased gradually (60% in 2004 vs. 67% in 2008) and 
cemented THA decreased steadily (19% in 2004 vs. 13% in 2008). Hybrid THA has 
remained approximately the same (21% in 2004 vs. 20% in 2008). CONCLUSIONS: 
The growth of joint replacement procedures performed follows an exponential func-
tion in the U.S. However, our study showed that the growth pattern in Germany 
follows a linear function for both THA and TKA. In the US, the number of procedures 
increased excessively among people aged between 45–64 years old, but this phenom-
enon was not observed in Germany. Another noticeable phenomenon was the ratio 
between hip and knee replacements. The number of TKA was approximately double 
compared with THA in the US. However, the number of TKA was slightly smaller 
than THA in Germany. In conclusion, Germany expects a slower and gradual increase 
in surgical loads of THA and TKA.
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OBJECTIVES: Doctors’ practice and prescribing patterns are based on many factors, 
some of which are not observable. We derived doctors’ prescribing patterns from U.S. 
claims data to show how it might be related with tumor necrosis factor (TNF) prescrip-
tion decisions. METHODS: Based on U.S. claims data, we assigned doctors’ IDs based 
on the physician who treated the enrollee for the longest period of time after eliminat-
ing any emergency room, laboratory, and radiology services. Physician prescribing 
patterns were then calculated from J-codes from the outpatient service and prescription 
drug records for TNF and non-TNF biologics. RESULTS: Among all TNF/anti-TNF 
prescribing doctors, patients who initiated their ﬁrst TNF therapy were prescribed 
etanercept 42.8% of the time, adalimumab 31.2%, inﬂiximab 21.1%, abatacept 
1.7%, anakinra 0.5%, and rituximab 0.8% of the time. If doctors’ practice/prescribing 
patterns favored TNF use or SubQ, patients were more likely to be switched to another 
TNF rather than to non-TNF biologics. CONCLUSIONS: Doctor’s prescribing pat-
terns are important factors for prescription decisions. Any outcomes research models 
such as compliance, adherence or treatment effect studies should incorporate these 
patterns. Models who fail to control for these variables might contain omitted variable 
bias.
